Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.
Location: United States, California, Encinitas
Employees: 11-50
Total raised: $68.4M
Founded date: 2007
Investors 3
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| 24.02.2024 | Aisling Ca... | aislingcap... |
| 20.01.2022 | aMoon Fund | amoon.fund... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.11.2021 | - | $50M | - |
| 05.04.2017 | Series B | $18.4M | - |
Mentions in press and media 25
| Date | Title | Description |
| 07.03.2024 | Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - |
| 31.01.2022 | Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors | SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the first patient has been dosed in the multinational Phase 1b/2 ... |
| 29.11.2021 | Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffus... | SAN DIEGO, Nov. 29, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted its all-o... |
| 08.11.2021 | Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance | SAN DIEGO - Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company primarily focused on targeting virus-associated malignancies, announced that the Company has entered into a loan and security agreement with Silicon Valley ... |
| 05.11.2021 | Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance - Form 8-K | Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance PR Newswire, San Diego, November 5, 2021 - Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company primarily focused on tar... |
| 05.11.2021 | Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance | SAN DIEGO, Nov. 5, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company primarily focused on targeting virus-associated malignancies, today announced that the Company has entered into a loan and secur... |
| 05.11.2021 | Viracta Therapeutics, Inc. Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance | ViractaTherapeutics, Inc. announced that the Company has entered into a loan and security agreement with Silicon Valley Bank (SVB) and Oxford Finance LLC (Oxford) for up to $50.0 million. In connection with the $50.0 million credit facility... |
| 16.08.2021 | Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors | |
| 21.07.2021 | Viracta Therapeutics : Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors | SAN DIEGO, July 21, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Administration (FDA) has cleared Viracta's... |
| 21.07.2021 | Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors |
Show more